Development of the Patient Harvey Bradshaw Index and a Comparison with a Clinician-based Harvey Bradshaw Index Assessment of Crohn's Disease Activity
Overview
Authors
Affiliations
Goals And Background: The objective is to develop a patient-based Harvey Bradshaw Index (P-HBI) of Crohn's Disease (CD) activity and to compare it with the clinician-based HBI of CD activity in CD outpatients.
Study: Consecutive patients with CD randomly completed the P-HBI either before or after the consultation. The gastroenterologist assessed patient's CD activity on the same day. Overall agreement between HBI and P-HBI was calculated with Spearman's ρ and Mann-Whitney U test. Agreement regarding active disease versus remission and agreement at item level was calculated by percent agreement and Cohen's κ.
Results: One hundred eighty-one (response rate 88.3%) CD patients participated. P-HBI and HBI showed a large correlation (rs=0.82). The medians (interquartile range) of the total HBI (2; 0 to 4) and P-HBI (4; 1 to 7) were statistically significantly different (z=-8.411; P<0.001). Fortunately, in 82.6% of the cases this difference between clinicians and patients was not clinically significant (<3.2). The percentage agreement between clinician and patient, judging CD as active or as in remission, was 77%, rs=0.56, κ=0.52, indicating a moderate agreement. P-HBI and HBI on frequent extraintestinal manifestations in CD varied from less than chance (κ=-0.02) to a perfect agreement (κ=1). Patients tended to report more symptoms while completing the patient-based questionnaire compared to what they reported to the clinician during consultation.
Conclusions: The P-HBI is the first step in developing a potential promising tool given its adequate agreement with the original HBI and its feasibility, especially in patients with low scores. Future research is necessary to develop a validated patient-based version studied in several patient populations.
Current approaches to studying human resting-state function in inflammatory bowel disease.
McIver T, Bernstein C, Kornelsen J J Can Assoc Gastroenterol. 2025; 8(Suppl 2):S36-S43.
PMID: 39990517 PMC: 11842902. DOI: 10.1093/jcag/gwae031.
Janssen L, van Linschoten R, West R, Gilissen L, Romberg-Camps M, Brandts L BMJ Open. 2024; 14(10):e076290.
PMID: 39375184 PMC: 11459379. DOI: 10.1136/bmjopen-2023-076290.
Barnes A, Bryant R, Mukherjee S, Andrews J, Bampton P, Fraser R Therap Adv Gastroenterol. 2024; 17:17562848241271987.
PMID: 39228998 PMC: 11369876. DOI: 10.1177/17562848241271987.
Barnes A, Bryant R, Mukherjee S, Spizzo P, Mountifield R JGH Open. 2024; 8(8):e70021.
PMID: 39185482 PMC: 11344164. DOI: 10.1002/jgh3.70021.
The potential of volatile organic compounds to diagnose primary sclerosing cholangitis.
van Vorstenbosch R, van Munster K, Stavropoulos G, Pachen D, van Schooten F, Ponsioen C JHEP Rep. 2024; 6(8):101103.
PMID: 39131082 PMC: 11315128. DOI: 10.1016/j.jhepr.2024.101103.